Christina Barrington, VP of pharmacy programs at Priority Health, spoke at AMCP Nexus 2021 about the value of managed care, real-world evidence and more.
Will Keytruda and Opdivo Finally Get Some Price Competition? | AMCP Nexus 2022
October 14th 2022EQRx has said it will price its PD-1/PDL-1 inhibitor 40% below the price of the entrenched PD-1/PDL-1 inhibitors, says Bhavesh Shah of Boston Medical Center Health System. But there are obstacles looming, including the development of combination therapies.
Read More
Trikafta Effective But Costly, Says Prime Therapeutics | AMCP Nexus 2022
October 14th 2022A real-world study by the PBM shows major benefits from the new cystic fibrosis drug when it comes to hospitalizations and pulmonary exacerbations. But total cost of care of patients tripled because the drug is expensive.
Read More
Gene Therapy Has Arrived. But So Will the $$$$$ Bills. | AMCP Nexus 2022
October 13th 2022Express Scripts' Aimee Tharaldson discussed the growing number of gene therapies in her keynote talk today on specialty drug at AMCP Nexus 2022. She listed 12 approved gene therapies, eight in the near-term pipeline for hemophilia and another seven for other diseases that may be approved next year.
Read More
Accumulators, Maximizers Exacerbate Healthcare Disparities, Says Janssen Research | AMCP Nexus 2022
October 13th 2022Research by Janssen shows that non-White patients are disproportionately affected by the accumulators and maximizers that PBMs use to blunt the financial consequences of copay assistance cards.
Read More
2 Clarke Drive
Cranbury, NJ 08512